Key result
De-escalating to clopidogrel 12 months post-AMI shows no difference in major events versus continuing prasugrel.
Why the study?
Guidelines recommend 12 months of potent P2Y12 inhibitor-based DAPT after AMI-DES PCI, but the optimal strategy beyond 1 year remains unclear.
Does de-escalating from prasugrel to clopidogrel at 12 months prevent cardiovascular events compared to continuing prasugrel in stabilized AMI patients post-PCI with DES?
Does de-escalating from prasugrel to clopidogrel at 12 months prevent cardiovascular events compared to continuing prasugrel in stabilized AMI patients post-PCI with DES?
De-escalating from prasugrel to clopidogrel at 12 months post-AMI PCI is a reasonable step-down strategy with comparable efficacy and safety to continuing prasugrel.
Answers are grounded in this paper and cite their sources.
No difference in events after de-escalation; leaves open whether switching is safe in broader post-AMI populations.
BACKGROUND: Guidelines recommend 12 months of potent P2Y12 inhibitor-based dual antiplatelet therapy after acute myocardial infarction-drug-eluting stents (AMI-DES) percutaneous coronary intervention, but the optimal strategy beyond 1 year remains unclear. We evaluated the clinical impact of de-escalating from prasugrel to clopidogrel at the 12-month landmark. METHODS: Using the nationwide Korea Acute Myocardial Infarction Registry-National Institutes of Health registry, we identified AMI patients who underwent successful percutaneous coronary intervention with DES and remained event free on aspirin-prasugrel (ASA/PSG) for 12 months. Patients were categorized into those who continued ASA/PSG or de-escalated to aspirin-clopidogrel (ASA/CPG). The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or stroke during months 12-24. Propensity score matching was used to adjust for confounders. RESULTS: Among 967 eligible patients, 384 continued ASA/PSG and 304 de-escalated to ASA/CPG. In the unmatched cohort, the cumulative incidence of the primary endpoint was lower in the ASA/CPG group (log-rank P = 0.045). In the propensity score matching cohort (250 pairs), there were no significant differences between the ASA/CPG and ASA/PSG groups for the primary endpoint (P = 0.316) or the secondary composite (P = 0.378). Absolute event rates were notably low in both groups; specifically, no definite/probable stent thrombosis or major bleeding occurred during the second year. Propensity score-adjusted Cox models confirmed these neutral findings (hazard ratio: 1.06, 95% confidence interval: 0.52-2.12). CONCLUSION: In stabilized AMI-DES survivors, de-escalating to clopidogrel at 12 months showed no significant difference in observed clinical outcomes compared with continued prasugrel, alongside a favorable safety profile. These findings suggest that clopidogrel-based de-escalation may be a reasonable step-down strategy in the second year, aligning with personalized therapy recommendations.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question. De-escalating to clopidogrel at 12 months post-AMI showed no significant difference in cardiovascular death, MI, or stroke compared to continuing prasugrel (HR 1.06, 95% CI 0.52-2.12).
Synapse has enriched 10 related papers. Consider them for comparative context: